Nat Med: Early treatment of COVID-19 with Anakinra under the guidance of plasma suPAR levels

An early increase in the level of soluble urokinase plasminogen activator receptor (suPAR) in serum indicates an increased risk of COVID-19 progression to respiratory failure
.

Recently, a research article was published in the top medical journal Nature Medicine.
The SAVE-MORE study was a double-blind, randomized controlled trial that evaluated the progress of anakinra (an IL-1α/β inhibitor) in 594 people.
For the efficacy and safety of COVID-19 patients with the risk of respiratory failure (such as plasma suPAR≥6ng/ml), 85.
9% (n=510) of the patients are receiving dexamethasone treatment
.

On the 28th day of the study, compared with placebo treatment, the adjusted proportion of patients with poorer clinical status after treatment with anakinra (as assessed by the World Health Organization 11-point Clinical Progress Scale (WHO-CPS)) was 0.
36 (95% confidence interval 0.
26-0.
50)
.

The median reduction in WHO-CPS scores from baseline in the placebo group and anakinra group on day 28 was 3 and 4, respectively (odds ratio (OR)=0.
40, P<0.
0001); sequential on day 7 The median reduction in organ failure assessment (SOFA) scores from baseline was 0 and 1 points, respectively (OR=0.
63, P=0.
004)
.

It can be seen that, compared with placebo, anakinra treated COVID-19 patients have a 0.
36 probability of having a worse clinical outcome on day 28
.

Evdoxia Kyriazopoulou,et al.